• Vol. 39 No. 11, 874–875
  • 15 November 2010

Bosentan – A Previously Unrecognised Cause of Facial Telangiectasia


Bosentan is an endothelin-1 (ET-1) receptor antagonist approved for the treatment of pulmonary artery hypertension (PAH). Although flushing is a documented side effect of bosentan, the diagnosis can mimic other drug rashes and medical conditions where facial telangiectasis and/or flushing are prominent presentation.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.